University of Chicago Pritzker School of Medicine, Chicago, IL, USA.
Illinois Department of Public Health, Chicago, IL, USA.
J Urban Health. 2019 Feb;96(1):38-48. doi: 10.1007/s11524-018-00329-x.
Opioid overprescribing is a major driver of the current opioid overdose epidemic. However, annual opioid prescribing in the USA dropped from 782 to 640 morphine milligram equivalents per capita between 2010 and 2015, while opioid overdose deaths increased by 63%. To better understand the role of prescription opioids and health care utilization prior to opioid-related overdose, we analyzed the death records of decedents who died of an opioid overdose in Illinois in 2016 and linked to any existing controlled substance monitoring program (CSMP) and emergency department (ED) or hospital discharge records. We found that of the 1893 opioid-related overdoses, 573 (30.2%) decedents had not filled an opioid analgesic prescription within the 6 years prior to death. Decedents without an opioid prescription were more likely to be black (33.3% vs 20.2%, p < .001), Hispanic (16.3% vs 8.8%, p < .001), and Chicago residents (46.8% vs 25.6%, p < .001) than decedents with at least one filled opioid prescription. Decedents who did not fill an opioid prescription were less likely to die of an overdose involving prescribed opioids (7.3% vs 19.5%, p < .001) and more likely to fatally overdose on heroin (63% vs 50.4%, p < .001) or fentanyl/fentanyl analogues (50.3% vs 41.8%, p = .001). Between 2012 and the time of death, decedents without an opioid prescription had fewer emergency department admissions (2.5 ± 4.2 vs 10.6 ± 15.8, p < .001), were less likely to receive an opioid use disorder diagnosis (41.3% vs 47.5%, p = .052), and were less likely to be prescribed buprenorphine for opioid use disorder treatment (3.3% vs 8.6%, p < .001). Public health interventions have often focused on opioid prescribing and the use of CSMPs as the core preventive measures to address the opioid crisis. We identified a subset of individuals in Illinois who may not be impacted by such interventions. Additional research is needed to understand what strategies may be successful among high-risk populations that have limited opioid analgesic prescription history and low health care utilization.
阿片类药物处方过量是当前阿片类药物过量流行的主要驱动因素。然而,2010 年至 2015 年期间,美国的阿片类药物年处方量从人均 782 吗啡毫克当量降至 640 吗啡毫克当量,而阿片类药物过量死亡人数增加了 63%。为了更好地了解与阿片类药物相关的过量用药之前处方阿片类药物和医疗保健利用的情况,我们分析了 2016 年伊利诺伊州死于阿片类药物过量的死者的死亡记录,并与任何现有的受控物质监测计划(CSMP)和急诊部(ED)或医院出院记录相关联。我们发现,在 1893 例阿片类药物相关过量中,573 例(30.2%)死者在死亡前 6 年内没有开出阿片类镇痛药处方。没有阿片类药物处方的死者更有可能是黑人(33.3%比 20.2%,p<0.001),西班牙裔(16.3%比 8.8%,p<0.001),芝加哥居民(46.8%比 25.6%,p<0.001)比至少开出一种阿片类药物处方的死者。没有开出阿片类药物处方的死者死于处方阿片类药物的过量的可能性较小(7.3%比 19.5%,p<0.001),更有可能因海洛因(63%比 50.4%,p<0.001)或芬太尼/芬太尼类似物(50.3%比 41.8%,p=0.001)致命过量。在 2012 年至死亡期间,没有阿片类药物处方的死者急诊就诊次数较少(2.5±4.2 次比 10.6±15.8 次,p<0.001),不太可能被诊断为阿片类药物使用障碍(41.3%比 47.5%,p=0.052),也不太可能被开处用于治疗阿片类药物使用障碍的丁丙诺啡(3.3%比 8.6%,p<0.001)。公共卫生干预措施通常侧重于阿片类药物处方和 CSMP 的使用,作为解决阿片类药物危机的核心预防措施。我们确定了伊利诺伊州的一部分人可能不会受到这些干预措施的影响。需要进一步研究以了解在阿片类药物镇痛处方史有限且医疗保健利用率低的高危人群中,哪些策略可能会成功。